Monoclonal gammopathy of undetermined significance (MGUS) can transform to multiple myeloma (MM). In myeloma, mutated V H genes with sequence homogeneity reveal a postfollicular origin. Previously, some MGUS cases showed mutated V H genes with intraclonal variation, indicating an earlier stage of arrest. We investigated progression from 2 of 2 MGUS to MM, in which V H genes confirmed clonal evolution. In one MGUS case, intraclonal heterogeneity was evident, and transformation to myeloma occurred rapidly with apparent homogeneity in the emergent clone. However, residual MGUS-derived sequences were detectable at this time. 
Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is defined by key criteria: a plasma cell infiltration of less than 10% of bone marrow mononuclear cells, serum monoclonal M-protein of equal to or less than 30 g/L, absence of lytic lesions, related anemia, hypercalcemia, and renal insufficiency. 1 MGUS varies in disease outcome, in some cases transforming to multiple myeloma (MM). Little is known concerning the underlying pathways of this progression, or indeed if the same clone is always involved. In part, these questions are hampered by the paucity of suitable tumor material for longitudinal analysis. More recently, evolution from MGUS to MM has been shown to exhibit a chromosome 13q abnormality. 2, 3 Analysis of immunoglobulin variable (V) region genes now provides a means of identifying salient features of B-cell tumor biology. Tumor V genes retain an imprint of the clonal history of the cell of origin. 4 They can reveal the impact of somatic mutation, most likely to have occurred in the germinal center (GC). 5 This is initiated in vitro by ligation of surface immunoglobulin (sIg) in normal and neoplastic B cells. [6] [7] [8] Tumors residing in the GC display intraclonal variation in V gene sequence patterns, a product of ongoing mutational activity at this site. 4, 9 Extensive data have characterized a postfollicular origin for MM, with more than 100 V H gene sequences displaying homogeneity of clonal tumor-derived sequences. 4 In contrast, 3 of 7 MGUS revealed significant intraclonal variation in V H sequence in tumor clones, suggesting at least in a subset of MGUS a maintenance of the mutational mechanism. 10 We now report 2 cases, evaluated during progression from MGUS to myeloma by V H gene analysis. Our findings reveal that the same tumor clone evolves to malignant status, and, importantly, analysis of somatic mutations suggests different pathways of disease progression.
Study design

Patients
Case 1 presented with advanced lung cancer with pulmonary involvement and a lesion in TH10. Immunofixation identified a trace IgA band. Bone-marrow (BM) biopsy (sample 1/1) revealed normal composition, with plasma cells (PCs) lower than 5%. Magnetic resonance imaging revealed infiltration of most vertebra 4 months later. Serum M-component was demonstrated (total IgA, 64 g/L; M level, not determined [ND]), with 80% PCs in BM (sample 1/2). A retrospective classification of TH10 could not rule out an isolated plasmacytoma at first biopsy; however, this had excluded any clinical marrow involvement. Further, postmortem examination revealed disseminated myeloma and confirmed concomitant squamouscell cancer with multiple pulmonary lesions, suggesting a possible metastatic TH10 spread.
Case 2 initially had an M-gradient in her serum electrophoresis (total IgG, 15.7 g/L; M level, ND; PCs, 5% of nucleated BM cells; sample 2/1) that progressed over 67 months (IgG, 26.6 g/L; BM PCs, 30%; sample 2/2). 
Cell preparation and V H gene analysis
BM aspirates were taken for magnetic activated cell sorting of CD138 ϩ cells. 11 Total RNA isolation from CD138 ϩ cells (1 ϫ 10 4 -2.6 ϫ 10 6 cells) and cDNA preparation using oligo-dT or constant region (C H ) primer were as described. 12 cDNA was amplified using V H 1-7 leader primers with 3Ј IgG or IgA primer. Cloning, sequence analysis, and V H gene alignments were as reported. 12 For V H genes, between 16 to 30 clones/sample were sequenced from 2 separate polymerase chain reactions (PCRs).
For each MGUS and MM sample, 246 to 258 bp of the tumor C H were amplified and cloned to establish the Taq error rate using single 5Ј complementary determining region 3 (CDR3) and C␥ or C␣ primers (916-3690 bp analyzed/sample). Taq error depends primarily upon the initial amount of template available. We used the same cDNA preparation and identical amounts of template input for V H and C H amplification. This corrected for variations in amount of RNA isolated and efficiency of cDNA synthesis, reflected in the range of Taq error observed in C H (3.4 ϫ 10 Ϫ4 to 1.6 ϫ 10 Ϫ3 bp Ϫ1 ). Replicate analysis confirmed Taq error.
Results and discussion
Case 1 utilized V 3-11 and case 2 V 4-30.2 in sequential samples. These showed evidence for extensive somatic mutations (nucleotide sequences have been deposited in the European Molecular Biology Laboratory database; accession numbers AJ536045-AJ536051).
We observed intraclonal variation in sequence at the MGUS stage in case 1. Mutations in codons 107TϾC and 120AϾG were identified in 2 respective clones obtained from separate PCRs (Figure 1 ). Additional single nucleotide changes were also observed (not shown), with a mutational frequency (1.6 ϫ 10 Ϫ3 bp Ϫ1 ) exceeding Taq errors in C H (3.4 ϫ 10 Ϫ4 bp Ϫ1 ; 11 clones from 2 PCRs). This confirms heterogeneity in MGUS. 10 It implicates a cell that is undergoing continual somatic mutation following tumorigenic arrest. This may be occurring in the GC environment, suggesting a less differentiated but sIg ϩ cell. [6] [7] [8] This cell has acquired a proliferative potential, perhaps due to a chromosomal event 1 (Figure 2 ). It allows progeny with heterogeneous sequences to survive and migrate to the marrow to differentiate further. This heterogeneity also exists in clonally derived C transcripts, demonstrated in only one MGUS case to date, 10 and implicating the stage of isotype switch in event 1.
Following transformation to myeloma in this patient (sample 1/2; Figure 1 ), the observed ongoing mutational activity appeared to be silenced, as the frequency of single nonclonal mutations (1.5 ϫ 10 Ϫ3 bp Ϫ1 ) was similar to Taq error (1.6 ϫ 10 Ϫ3 bp Ϫ1 ). However, we observed 2 mutational changes at codons 68TϾC and 107TϾC in single clones at the MM stage that were identical to mutations at the early stage of disease (Figure 1 ). These 2 mutations were detected in samples taken at 2 different disease stages, negating random PCR error. Most likely, they represent residual MGUS clones as transformation was rapid. In the absence of paired samples, a very low level of nonshared mutations in some MM clones would have been assigned as Taq error in V gene analysis. Reports of stability of myeloma V gene sequence indicate the rarity of identifying such persisting residual clones by current technology. 4 However, there have been sporadic reports that hint at this possibilty. In 1 of 4 MM cases with more than 40% tumor cells, 2 clonally-related subclones with heterogeneity were observed, 13 possibly reflecting a narrowing of a wider variation that existed previously. In a further MM case, significant intraclonal diversity was noted in the IgA variant transcripts but not the tumor isotype, suggesting emergence of a dominant clone but with residual variants. 14 Given that MM is clonally homogeneous even in C tumor-derived sequences, [15] [16] [17] this suggests that the final transformation event (event 2, Figure 2 ) occurs in one cell of the population, at a site where somatic mutation is silent, possibly the bone marrow.
In case 2, we observed intraclonal homogeneity at both the MGUS and MM stage, confirming previous observations in 4 of 7 MGUS cases. 10 A self-cloning phenomenon may underlie this observed sequence homogeneity in MGUS, being analyzed at a stage where hypermutation has ceased and heterogeneity has been lost because of clonal outgrowth. Transformation to myeloma then occurs at the invariant stage, involving event 2 (Figure 2) . Mutational patterns in VH genes define diversity in MGUS, with some cases showing intraclonal heterogeneity. Plasma cells in these MGUS cases most likely derive by maturation of a less differentiated sIg ϩ cell that is undergoing somatic mutation and has acquired a chromosomal event 1 to gain a proliferative potential. Transformation to myeloma can clearly occur in MGUS displaying heterogeneity, but does so in a single cell in which somatic mutation is silent and that acquires neoplastic event 2. This transformation may be rapid, and residual MGUS clones can still be identified at this time but will eventually be lost by clonal outgrowth as myeloma is homogeneous. A self-cloning process may also lead to the MGUS cases identified by intraclonal stability of sequence, which are more common. These cases can then transform to myeloma as a result of event 2. VDJ indicates functionally rearranged variablediversity-joining gene.
V H gene analysis has revealed diversity in MGUS and has suggested that transformation may involve different pathways. MGUS may derive from an tumorigenic sIg ϩ cell undergoing somatic mutation, which differentiates into Ig-secreting plasma cells. This population may persist and possibly self clone to homogeneity. However, it is susceptible to further transforming events that can occur in one cell at the heterogeneous or homogeneous stage, giving rise to homogeneous MM that is independent of the sIg ϩ population. Progression to myeloma then involves factors intrinsic to this cell.
